The dual GIP/GLP-1 peptide agonist tirzepatide reversed diabetes-induced male reproductive dysfunction in rats by activating antioxidant pathways and restoring hormone levels, with effects largely independent of weight loss and superior to metformin.
Weight-independent protectionTirzepatide's reproductive benefits were largely independent of weight loss, confirmed by a pair-fed control group, pointing to direct tissue-protective actions of the peptide drug
What the researchers found
In diabetic Wistar rats treated for eight weeks, tirzepatide produced comprehensive reproductive improvements: restored testosterone and gonadotropin levels, enhanced sperm quality, reduced lipid peroxidation (oxidative fat damage), and preserved testicular architecture with increased PCNA expression (cell proliferation) and reduced caspase-3-mediated apoptosis (programmed cell death).
The protective mechanism involved activation of the Nrf2/Keap1 antioxidant pathway and normalization of steroidogenic gene expression. Crucially, a pair-fed diabetic control group demonstrated that these effects were largely independent of weight reduction — pointing to direct tissue-protective actions of tirzepatide. All reproductive outcomes were superior to those achieved with metformin.
Why it matters
Male infertility affects up to 50% of men with type 2 diabetes, and current diabetes treatments like metformin have limited ability to reverse reproductive damage. The finding that tirzepatide — a peptide drug already FDA-approved for diabetes and obesity — has direct reproductive protective effects independent of weight loss and blood sugar improvement opens a potential secondary benefit for millions of diabetic men struggling with fertility.
How the study worked
Sixty Wistar rats were divided into five groups: control, diabetic control, tirzepatide-treated diabetic, metformin-treated diabetic, and pair-fed diabetic control (to isolate weight-independent effects). Diabetes was induced using a high-fat diet combined with low-dose streptozotocin. Treatments were administered for eight weeks. Comprehensive assessments included metabolic parameters, reproductive hormones, sperm analysis, oxidative stress markers, testicular histology, and gene expression analysis for antioxidant (Nrf2/Keap1), steroidogenic, proliferative (PCNA), and apoptotic (caspase-3) markers.
What this study cannot tell us
This is a rat study using chemically induced diabetes, which may not fully replicate human type 2 diabetes. The eight-week treatment period is relatively short. The pair-fed control design helps isolate weight-independent effects but doesn't perfectly control for all metabolic differences. Translation to human male fertility requires clinical trials — rat reproductive biology differs significantly from human. Specific tirzepatide doses used in the rat model may not correspond to clinically relevant human doses.
How to read the evidence
This is a well-designed preclinical study with five experimental groups including a pair-fed control — an important methodological feature for separating weight-dependent from weight-independent drug effects. The comprehensive outcome measures strengthen the findings. However, as an animal study, direct clinical translation requires human trials.
When this study was published
Published in 2026, this is a very recent study exploring the expanding therapeutic applications of tirzepatide beyond its approved metabolic indications.
The bigger picture
Tirzepatide is the first dual GIP/GLP-1 receptor agonist, and its tissue-protective effects beyond metabolic control are still being discovered. This study adds reproductive function to the growing list of organs that benefit from incretin peptide signaling — including heart, kidneys, brain, and liver. The weight-independent protective mechanism via Nrf2/Keap1 antioxidant activation is particularly significant, as it suggests peptide receptor agonism directly counteracts the oxidative damage that drives many diabetes complications.
Questions still open
- Do men with type 2 diabetes who take tirzepatide experience improvements in testosterone levels and fertility in clinical practice?
- Could tirzepatide's Nrf2/Keap1 activation protect other organs from diabetes-related oxidative damage beyond the testes?
- Would combining tirzepatide with targeted antioxidant supplements enhance the reproductive protective effects?
Common questions
How does diabetes damage male fertility?
What is the Nrf2/Keap1 pathway and why does it matter?
Read the original research
Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.
Toxicology research, 15(1), tfag010
Citation
Albokhadaim, Ibrahim. (2026). Tirzepatide ameliorates type 2 diabetes-associated male reproductive dysfunction via modulation of the Nrf2/Keap1 pathway.. Toxicology research, 15(1), tfag010. https://doi.org/10.1093/toxres/tfag010